OraSure Technologies shares rose 4.3% following a quarter that delivered revenue growth and gross margin expansion, supported by progress in near-shoring initiatives and product pipeline advancement that appear to have reassured investors about future prospects.

• Total revenue reached $27.9 million, above the midpoint of guidance, with a 4% sequential increase.
• Diagnostics revenue grew 12% sequentially to $16.9 million, split evenly between U.S. and international markets.
• Sample Management Solutions revenue remained flat at $9.1 million, held back by muted NIH-related demand.
• Gross margin improved to 43.4% on a non-GAAP basis, driven by in-sourcing production and manufacturing efficiencies.
• R&D expense rose to $13.7 million due to launch preparations for two FDA-pending products expected to drive growth starting in the second half of 2026.